問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Dalin Tzu Chi Hospital Buddhist Tzu Chi Medical Foundation (在職)

Division of Rheumatology

Hualien Tzu Chi Hospital (在職)

更新時間：2023-09-19

童建學
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

7Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

童建學

List

21Cases

2019-10-31 - 2023-10-05

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2018-12-20 - 2027-01-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

黃毓惠
Linkou Chang Gung Medical Foundation

Division of Dermatology

2016-04-01 - 2020-11-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated3Sites

藍忠亮
China Medical University Hospital-Taipei

未分科

2021-10-01 - 2023-08-04

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-10-01 - 2027-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2023-05-31 - 2027-09-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-12-14 - 2026-01-01

Phase III

Active
A multi-center, randomized, double-blind, active-controlled, therapeutic confirmatory, phase III study to compare and evaluate the efficacy and safety of Epaminurad with Febuxostat in gout patients

  • Condition/Disease

    gout

  • Test Drug

    Epaminurad

Participate Sites
13Sites

Not yet recruiting1Sites

Recruiting12Sites

2022-12-14 - 2026-01-01

Phase III

A Multi-center, Randomized, Double-blind, Active-controlled, Therapeutic Confirmatory, Phase III Study to Compare and Evaluate the Efficacy and Safety of Epaminurad With Febuxostat in Gout Patients

  • Condition/Disease

    Gout

  • Test Drug

    Epaminurad

Participate Sites
13Sites

Not yet recruiting1Sites

Recruiting12Sites

2007-05-01 - 2009-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Study ended11Sites

2018-11-01 - 2022-04-30

Phase III

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus

  • Condition/Disease

    Systemic Lupus Erythematosus

  • Test Drug

    Baricitinib

Participate Sites
9Sites

Recruiting7Sites

Terminated2Sites

方耀凡
Linkou Chang Gung Medical Foundation

Division of Rheumatology

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB